留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

抗缪勒管激素的临床应用

邱玲 李丹丹 程歆琦

邱玲, 李丹丹, 程歆琦. 抗缪勒管激素的临床应用[J]. 协和医学杂志, 2017, 8(4-5): 229-234. doi: 10.3969/j.issn.1674-9081.2017.05.007
引用本文: 邱玲, 李丹丹, 程歆琦. 抗缪勒管激素的临床应用[J]. 协和医学杂志, 2017, 8(4-5): 229-234. doi: 10.3969/j.issn.1674-9081.2017.05.007
Ling QIU, Dan-dan LI, Xin-qi CHENG. Clinical Application of Anti-Müllerian Hormone[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 229-234. doi: 10.3969/j.issn.1674-9081.2017.05.007
Citation: Ling QIU, Dan-dan LI, Xin-qi CHENG. Clinical Application of Anti-Müllerian Hormone[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 229-234. doi: 10.3969/j.issn.1674-9081.2017.05.007

抗缪勒管激素的临床应用

doi: 10.3969/j.issn.1674-9081.2017.05.007
详细信息
    通讯作者:

    邱玲  电话:010-69159702,E-mail:lingqiubj@aliyun.com

  • 中图分类号: R446.11+2

Clinical Application of Anti-Müllerian Hormone

More Information
  • 摘要: 抗缪勒管激素(anti-Müllerian hormone, AMH)是由女性卵泡颗粒细胞和男性睾丸支持细胞分泌的二聚体糖蛋白, 可抑制女性卵泡的募集和生长, 调节男性睾丸间质细胞的功能。目前文章多阐述其临床应用:检测血清AMH的水平可用于评估卵巢储备, 预测辅助生殖过程中的卵巢反应, 评估肿瘤患者卵巢储备, 辅助诊断多囊卵巢综合征、卵巢早衰及预测绝经等, 但对其检测方法和参考区间研究阐述较少。近年来, 随着AMH检测技术的发展, 临床应用领域越来越广泛, 本文就AMH的生理、临床应用、检测方法和参考区间等问题进行深入探讨。
  • 图  1  AMH的血清学检测发展史

    AMH:抗缪勒管激素

  • [1] Wilson CA, di Clemente N, Ehrenfels C, et al. Müllerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily[J]. Mol Endocrinol, 1993, 7:247-257. https://www.ncbi.nlm.nih.gov/pubmed/8469238
    [2] Di Clemente N, Wilson C, Faure E, et al. Cloning, expression and alternative splicing of the receptor for anti-Müllerian hormone[J]. Mol Endocrinol, 1994, 8:1006-1020. https://www.ncbi.nlm.nih.gov/pubmed/7997230
    [3] Jamil Z, Fatima SS, Ahmed K, et al. Anti-Müllerian hormone:above and beyond conventional ovarian reserve markers[J]. Dis Markers, 2016:5246217. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764725/
    [4] Matzuk MM, Lamb DJ. The biology of infertility:research advances and clinical challenges[J]. Nat Med, 2008, 14:1197-1213. doi:  10.1038/nm.f.1895
    [5] Josso N, Rey RA, Picard JY. Anti-Müllerian hormone:a valuable addition to the toolbox of the pediatric endocrinologist[J]. Int J Endocrinol, 2013, 2013:674105. https://www.researchgate.net/profile/Rodolfo_Rey/publication/259560314_Anti-Mullerian_Hormone_A_Valuable_Addition_to_the_Toolbox_of_the_Pediatric_Endocrinologist/links/0046353bd3195d1680000000/Anti-Muellerian-Hormone-A-Valuable-Addition-to-the-Toolbox-of-the-Pediatric-Endocrinologist.pdf
    [6] Lee MM, Donahoe PK. Müllerian inhibiting substance:a gonadal hormone with multiple functions[J]. Endocr Rev, 1993, 14:152-164. https://www.sciencedirect.com/science/article/pii/S0015028297814173
    [7] Weenen C, Laven JS, Von Bergh AR, et al. Anti-Müllerian hormone expression pattern in the human ovary:potential implications for initial and cyclic follicle recruitment[J]. Mol Hum Reprod, 2004, 10:77-83. doi:  10.1093/molehr/gah015
    [8] Kelsey TW, Wright P, Nelson SM, et al. A validated model of serum anti-müllerian hormone from conception to menopause[J]. PLoS One, 2011, 16:e22024. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Open J-Gate000003875995
    [9] Broekmans FJ, Visser JA, Laven JS, et al. Anti-Müllerian hormone and ovarian dysfunction[J]. Trends Endocrinol Metab, 2008, 19:340-347. doi:  10.1016/j.tem.2008.08.002
    [10] Seifer DB, Maclaughlin DT. Müllerian inhibiting substance is an ovarian growth factor of emerging clinical significance[J]. Fertil Steril, 2007, 88:539-546. doi:  10.1016/j.fertnstert.2007.02.014
    [11] Rosen MP, Johnstone E, McCulloch CE, et al. A characterization of the relationship of ovarian reserve markers with age[J]. Fertil Steril, 2012, 97:238-243. doi:  10.1016/j.fertnstert.2011.10.031
    [12] La Marca A, Giulini S, Tirelli A, et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology[J]. Hum Reprod, 2006, 22:766-771. https://www.ncbi.nlm.nih.gov/pubmed/17071823
    [13] Koninger A, Koch L, Enekwe A, et al. Change of anti-Müllerian hormone levels during follicular phase in PCOS patients[J]. Gynecol Endocrinol, 2015, 31:26-30. doi:  10.3109/09513590.2014.959436
    [14] Fanchin R, Taieb J, Lozano DH, et al. High reproducibility of serum anti-Müllerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status[J]. Hum Reprod, 2005, 20:923-927. doi:  10.1093/humrep/deh688
    [15] Mertens AC, Yong J, Dietz AC, et al. Conditional survival in pediatric malignancies:analysis of data from the Childhood Cancer Survivor Study and the Surveillance, Epidemiology, and End Results Program[J]. Cancer, 2015, 121:1108-1117. doi:  10.1002/cncr.29170
    [16] Barnabei A, Strigari L, Marchetti P, et al. Predicting ovarian activity in women affected by early breast cancer:A Meta-analysis-based nomogram[J]. Oncologist, 2015, 20:1111-1118. doi:  10.1634/theoncologist.2015-0183
    [17] Iwase A, Nakamura T, Nakahara T, et al. Assessment of ovarian reserve using anti-Müllerian hormone levels in benign gynecologic conditions and surgical interventions:a systematic narrative review[J]. Reprod Biol Endocrinol, 2014, 12:125. doi:  10.1186/1477-7827-12-125
    [18] Henry NL, Xia R, Schott AF, et al. Prediction of postchemotherapy ovarian function using markers of ovarian reserve[J]. The Oncologist, 2014, 19:68-74. doi:  10.1634/theoncologist.2013-0145
    [19] Anderson RA, Rosendahl M, Kelsey TW, et al. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer[J]. European Journal of Cancer, 2013, 49:3404-3411. doi:  10.1016/j.ejca.2013.07.014
    [20] Iwase A, Nakamura T, Nakahara T, et al. Anti-Mullerian hormone and assessment of ovarian reserve after ovarian toxic treatment:a systematic narrative review[J]. Reprod Sci, 2015, 22:519-526. doi:  10.1177/1933719114549856
    [21] Nelson SM, Yates RW, Lyall H, et al. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception[J]. Hum Reprod, 2009, 24:867-875. https://academic.oup.com/humrep/article/24/4/867/632894
    [22] Broer SL, van Disseldorp J, Broeze KA, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy:an individual patient data approach[J]. Hum Reprod Update, 2013, 19:26-36. doi:  10.1093/humupd/dms041
    [23] Broer SL, Dolleman M, van Disseldorp J, et al. Prediction of an excessive response in in vitro fertilization from patient cha-racteristics and ovarian reserve tests and comparison in subgroups:an individual patient data meta-analysis[J]. Fertil Steril, 2013, 100:420-429. doi:  10.1016/j.fertnstert.2013.04.024
    [24] Li R, Gong F, Zhu Y, et al. Anti-Müllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles:a prospective, multi-centre, observational study[J]. Reprod Bio Med Online, 2016, 33:506-512. doi:  10.1016/j.rbmo.2016.07.003
    [25] Nelson SM, Klein BM, Arce J C. Comparison of anti Müllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials[J]. Fertil Steril, 2015, 103:923-930. doi:  10.1016/j.fertnstert.2014.12.114
    [26] La Marca A, Sunkara SK. Individualization of controlled ova-rian stimulation in IVF using ovarian reserve markers:from theory to practice[J]. Hum Reprod Update, 2014, 20:124-140. doi:  10.1093/humupd/dmt037
    [27] Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing:a sea change in determining ovarian reserve using anti-müllerian hormone[J]. Fertil Steril, 2013, 99:1825-1830. doi:  10.1016/j.fertnstert.2013.03.001
    [28] Dewailly D.Diagnostic criteria for PCOS:Is there a need for a rethink?[J]. Best Pract Res Clin Obstet Gynaecol, 2016, 37:5-11. doi:  10.1016/j.bpobgyn.2016.03.009
    [29] Laven JS, Mulders AG, Visser JA, et al. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age[J]. J Clin Endocrinol Metab, 2004, 89:318-323. doi:  10.1210/jc.2003-030932
    [30] Das M, Gillott DJ, Saridogan E, et al. Anti-Müllerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome[J]. Hum Reprod, 2008, 23:2122-2126. doi:  10.1093/humrep/den185
    [31] Tal R, Seifer DB, Khanimov M, et al. Characterization of women with elevated antimüllerian hormone levels(AMH):correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes[J]. Am J Obstet Gynecol, 2014, 211:59, e1-e8. https://www.ncbi.nlm.nih.gov/pubmed/24593938
    [32] Iliodromiti S, Kelsey TW, Anderson RA, et al. Can anti-Müllerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data[J]. J Clin Endocrinol Metab, 2013, 98:3332-3340. doi:  10.1210/jc.2013-1393
    [33] Broer SL, Eijkemans MJ, Scheffer GJ, et al. Anti-müllerian hormone predicts menopause:a long-term follow-up study in normoovulatory women[J]. J Clin Endocrinol Metab, 2011, 96:2532-2539. doi:  10.1210/jc.2010-2776
    [34] Dolleman M, Depmann M, Eijkemans MJ, et al. Anti-Müllerian hormone is a more accurate predictor of individual time to menopause than mother's age at menopause[J]. Hum Reprod, 2014, 29:584-591. doi:  10.1093/humrep/det446
    [35] Dolleman M, Verschuren WM, Eijkemans MJ, et al. Added value of anti-Müllerian hormone in prediction of menopause:results from a large prospective cohort study[J]. Hum Reprod, 2015, 30:1974-1981. doi:  10.1093/humrep/dev145
    [36] Knauff EA, Eijkemans MJ, Lambalk CB, et al. Anti-Müllerian hormone, inhibin B, and antral follicle count in young women with ovarian failure[J]. J Clin Endocrinol Metab, 2009, 94:786-792. doi:  10.1210/jc.2008-1818
    [37] La Marca A, Volpe A. The Anti-Müllerian hormone and ova-rian cancer[J]. Hum Reprod Update, 2007, 13:265-273. doi:  10.1093/humupd/dml060
    [38] Farkkila A, Koskela S, Bryk S, et al. The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors-a comparative study with inhibin B[J]. Int J Cancer, 2015, 137:1661-1671. doi:  10.1002/ijc.29532
    [39] Rey RA, Lhommé C, Marcillac I, et al. Anti-müllerian hormone as a serum marker of granulosa cell tumorsof the ovary:comparative study with serum alpha-inhibin and estradiol[J]. Am J Obstet Gynecol, 1996, 174:958-965. doi:  10.1016/S0002-9378(96)70333-2
    [40] Josso N, Rey RA, Picard JY. Anti-müllerian hormone:a valuable addition to the toolbox of the pediatric endocrinologist[J]. Int J Endocrinol, 2013:674105. https://www.hindawi.com/journals/ije/2013/674105/fig1/
    [41] Aksglaede. 2014 AUA Guideline[S]. 2010.
    [42] Pearson K, Long M, Prasad J, et al. Assessment of the Access AMH assay as an automated, high-performance replacement for the AMH Generation Ⅱ manual ELISA[J]. Reprod Biol Endocrinol, 2016, 14:8. doi:  10.1186/s12958-016-0143-3
    [43] Nelson SM, Pastuszek E, Kloss G, et al. Two new automated, compared with two enzyme-linked immunosorbent, antimüllerian hormone assays[J]. Fertil Steril, 2015, 104:1016-1021. doi:  10.1016/j.fertnstert.2015.06.024
    [44] Abma JC, Chandra A, Mosher WD, et al. Fertility, family planning, and women's health:new data from the 1995 National Survey of Family Growth[J]. Vital and Health Statistics, 1997, 19:1-114. http://cn.bing.com/academic/profile?id=b3a9874513a1e1c7fee09ba68960bf14&encoded=0&v=paper_preview&mkt=zh-cn
    [45] Bleil ME, Gregorich SE, Adler NE, et al. Race/ethnic disparities in reproductive age:an examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling women[J]. Fertil Steril, 2014, 101:199-207. doi:  10.1016/j.fertnstert.2013.09.015
    [46] Du X, Ding T, Zhang H, et al.Age-specific normal reference range for serum anti-müllerian hormone in healthy chinese han women:a nationwide population-based study[J]. Reprod Sci, 2016, 23:1019-1027. doi:  10.1177/1933719115625843
  • 加载中
图(1)
计量
  • 文章访问数:  27
  • HTML全文浏览量:  1
  • PDF下载量:  4
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-03-03
  • 刊出日期:  2017-09-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!